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Background: Gastrointestinal stromal tumors (GISTs) are the most common mesenchymal neoplasms. However,
duodenal GISTs compromise a small and rare subset and few studies have focused on them. We evaluated the
surgical management of patients with duodenal GISTs treated by pancreaticoduodenectomy (PD) versus local
resection (LR) in our institution and analyzed the postoperative outcomes.
Methods: This was a retrospective review of patients with duodenal GISTs managed in our institution from January 2006
to January 2012. Clinicopathologic findings and disease-free survival (DFS) of duodenal GIST patients were analyzed.
Results: A total of 48 patients were selected. The most common presentation was bleeding (60.4%), and the second
portion of the duodenum (35.4%) was the most common dominant site. Of the patients, 34 (70.8%) underwent LR while
14 (29.2%) underwent PD. The surgical margins for all studied patients were free. Patients who ultimately underwent PD
were more likely to present with a larger tumor (median size: PD, 6.3 cm vs LR, 4.0 cm; P = 0.02) and more commonly
presented with a tumor in the second portion of the duodenum (second portion: PD, 64.3% vs LR, 23.5%; P = 0.007). The
tumors treated by PD had a higher grade of risk compared with LR as defined by National Institutes of Health (NIH)
criteria (P = 0.019). PD was significantly associated with a longer operation time and a longer hospital stay compared to
LR (P < 0.001 and P = 0.001, respectively). In our study, the median follow-up period was 36 months (range: 0 to
81 months). The 1- and 3-year DFS was 100% and 88%, respectively. From multivariable analysis, the only significant factor
associated with a worse DFS was an NIH high risk classification (hazard ratio = 4.24).
Conclusions: The recurrence of duodenal GIST was correlated to tumor biology rather than type of operation. PD was
associated with a longer hospital stay and longer operation time. Therefore, LR with clear surgical margins should be
considered a reliable and curative option for duodenal GIST and PD should be reserved for lesions not amenable to LR.
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Gastrointestinal stromal tumors (GISTs) are the most
common mesenchymal tumors of the gastrointestinal
(GI) tract. They can occur in the stomach (45% to 65%),
small intestine (15% to 25%), colon and rectum (5% to
10%) or esophagus (5% to 10%) [1]. The clinical manifes-
tations of GISTs are variable and render accurate diag-
nosis challenging. The current diagnosis of GIST is
based on histologic and immunohistochemical criteria,* Correspondence: shusenzheng@zju.edu.cn
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reproduction in any medium, provided the orthe most important of which is the expression of the re-
ceptor tyrosine kinase KIT (CD117, c-Kit) [1,2]. Duo-
denal GISTs are a very rare presentation, accounting for
approximately 20% of tumors in the small intestine and
1% to 4% of all GISTs [3].
Complete surgical resection remains the best option for
the treatment of GISTs, although imatinib mesylate, a
tyrosine kinase inhibitor, is effective for GISTs. Unlike gas-
tric GISTs, which can be adequately treated by wedge re-
section instead of formal gastrectomy, the optimal surgical
procedures for duodenal GISTs have not been well charac-
terized in the surgical literature [3-9]. Some authors advo-
cate radical procedures like pancreaticoduodenectomytd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
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such as segmental duodenectomy and local or wedge re-
section (LR) based on their biology: since they are encap-
sulated tumors, GISTs do not widely infiltrate at the
microscopic level and rarely metastasize to lymph nodes.
In this study, we retrospectively reviewed the clinicopatho-
logic characteristics of duodenal GISTs in our institution
and compared the outcomes of patients undergoing PD
versus LR with the main objective of determining if LR is
a viable treatment option for these tumors.
Methods
A total of 48 patients who underwent surgical resection
for a duodenal GIST were retrospectively reviewed from
January 2006 to January 2012 at the First Affiliated Hos-
pital, Zhejiang University School of Medicine. The pre-
operative diagnosis of a duodenal GIST was made through
computed tomography or endoscopy. Furthermore, the
precise diagnosis of GIST was made based on the standard
histologic criteria. Complete tumor removal, either LR or
PD, was the treatment in each case. In general, following
LR the duodenal defect was closed primarily when pos-
sible or with a Roux-en-Y duodenojejunostomy when pri-
mary closure was not possible. Routine lymphadenectomy
was not performed. The following characteristics were col-
lected for each patient: age, sex, presenting symptoms, lo-
cation of primary tumor, pathologic features including
tumor size, mitotic count, immunohistochemistry, opera-
tive method, complications and the most recent follow-up
information. Data on the use of preoperative or postopera-
tive therapies including imatinib and chemotherapy were
also recorded.
The primary study end point was disease-free survival
(DFS), which was defined as the time from surgery to
GIST recurrence. Patients who did not have evidence of
local recurrence or metastasis at the last follow-up and
those who died from causes unrelated to GIST were ex-
cluded from the DFS analysis. Furthermore, we analyzed
prognostic factors, including age, sex (male versus female),
clinical presentation (asymptomatic versus symptomatic),
risk classification (high versus intermediate, low and very
low) and operative method (PD versus LR).
Statistical analysis
Our results are given as medians (plus ranges) and all stat-
istical analyses were performed using the software SPSS
16.0 (SPSS, Chicago, IL) for Windows. Comparisons of
the clinicopathologic characteristics between the two sur-
gical groups were assessed using the chi-squared test for
dichotomous and categorical variables. DFS was calculated
using the Kaplan–Meier method and differences between
the groups were evaluated using the log-rank test. Cox
proportional hazard models were used to estimate hazard
ratios for DFS and to determine independent risk factors.Statistical significance was defined as P values less than
0.05, and all tests were 2-sided.
Consent and statement of ethical approval
Written informed consent was obtained from all partici-
pants. This study was approved by the local Ethics Com-
mittee at Zhejiang University School of Medicine.
Results
Clinicopathologic characteristics of duodenal
gastrointestinal stromal tumors
In total, 48 patients who had presented with duodenal
GISTs during the study period were included in the ana-
lysis (28 men, 20 women). The median age at presentation
was 53 years (range: 27 to 89 years). Of 48 duodenal GISTs,
8 (16.7%) were found incidentally during a health examin-
ation. The most common presentation of a symptomatic
duodenal GIST was gastrointestinal bleeding, which was
seen in 29 (60.4%) patients, followed by abdominal discom-
fort seen in 7 (14.6%), abdominal pain seen in 3 (6.3%) and
jaundice seen in 1 (2%; Table 1). None of the patients had
a history of neurofibromatosis. The duodenal GISTs were
located at the first (D1) (n = 11, 22.9%), second (D2) (n =
17, 35.4%), third (D3) (n = 6, 12.5%) or fourth portion of
the duodenum (D4) (n = 2, 4.2%), or they involved both
D1/D2 (n = 8, 16.7%) or D2/D3 (n = 4, 8.3%). The median
size of the duodenal GISTs was 4.7 cm (range: 2.0 to
15.0 cm). A low mitotic count was found in 75% of the
duodenal GISTs. The numbers of patients classified as
low risk, intermediate risk and high risk were 28
(58.3%), 11 (22.9%) and 9 (18.8%), respectively. Immu-
nohistochemically, 97.9% of the duodenal GISTs were
positive for CD117, 66.7% for CD34, 12.5% for desmin
and 10.4% for S-100 (Table 1). Only one GIST was
CD117 and desmin negative; however, it stained posi-
tively for CD34 and SMA.
Comparison of clinicopathological features between
tumors treated by PD and by LR
All of the patients underwent a curative resection (R0),
and there were 14 PDs and 34 LRs. Comparing PD with
LR, many of the clinicopathological characteristics in the
two cohorts showed no significant differences, including
sex, presence of symptoms, complications, Eastern Co-
operative Oncology Group (ECOG) scores and recur-
rence rates (Table 2). However, the age of patients who
underwent PD was older (median age: PD, 59 years vs
LR, 51 years; P = 0.03). Meanwhile, patients who ultim-
ately underwent PD were more likely to present with a
larger tumor (median size: PD, 6.3 cm vs LR, 4.0 cm;
P = 0.02) and more commonly presented with a tumor
in the second portion of the duodenum (second portion:
PD, 64.3% vs LR, 23.5%; P = 0.007). Also, the tumors
treated by PD had a higher grade of risk compared with
Table 1 Clinical and pathological characteristics for
patients with a duodenal GIST
Variable All patients (n = 48)
Age
Median 53 years






Incidental finding 8 (16.7%)
Abdominal discomfort 7 (14.6%)




Range 2.0 to 15.0 cm
Mitotic count
≤5 mitosis/50 HPF 36 (75.0%)
6 to 10 mitosis/50 HPF 4 (8.3%)
mitosis HPF 8 (16.7%)
NIH risk classification
Low risk 28 (58.3%)
Intermediate risk 11 (22.9%)




















D1, first part of the duodenum; D2, second part of the duodenum; D3, third
part of the duodenum; D4, fourth part of the duodenum; NIH, National
Institutes of Health.
Table 2 Comparison between local resection versus







Male 19 (55.9%) 9 (64.3%) 0.59
Age (years) 51 (27 to 89) 59 (36 to 72) 0.03
Presentation 0.28
Bleeding 23 (64.7%) 6 (42.9%)
Incidental
finding
4 (11.8%) 4 (28.6%)
Abdominal
discomfort
5 (17.6%) 2 (14.3%)
Abdominal
pain
2 (5.9%) 1 (7.1%)
Jaundice 0 1 (7.1%)
Size (cm) 4.0 (2.0 to 7.0) 6.3 (2.5 to 15.0) 0.02
Site
D1 9 (26.5%) 2 (14.3%)
D2 8 (23.5%) 9 (64.3%) 0.007
D3 6 (17.6) 0
D4 2 (5.9%) 0
D1/D2 6 (17.7%) 2 (14.3%)
D2/D3 3 (8.8%) 1 (7.1%)
NIH risk criteria 0.019
Low risk 23 (67.7%) 5 (35.7%)
Intermediate
risk
8 (23.5%) 3 (21.4%)





395 (240 to 600) <0.001
Postoperative
stay (days)
14 (11 to 35) 21 (12 to 46) 0.001
Complications 4 (11.8%) 5 (35.7%) 0.053
ECOG scores 0 (0 to 5) 0 (0 to 1) 0.80
Mortality 2 (5.9%) 0 0.35
Recurrence 1 (2.9%) 2 (14.3%) 0.14
D1, first part of the duodenum; D2, second part of the duodenum; D3, third
part of the duodenum; D4, fourth part of the duodenum; ECOG, Eastern
Cooperative Oncology Group; NIH, National Institutes of Health.
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teria (P = 0.019). In addition, PD was significantly associ-
ated with a longer operation time and a longer hospital stay
compared to LR (P < 0.001 and P = 0.001, respectively).
Postoperative course details and long-term outcomes
Postoperative complications occurred in nine duodenal
GIST patients, comprising five who underwent PD and
four who underwent LR. These complications were pan-
creatic fistulas, duodenal leaks, wound infections, intra-
abdominal hemorrhages and death. None of the 48
Table 4 Multivariable analysis of factors for being





Age (>65 years) 0.52 (0.17 to 1.56) 0.34
Sex (male) 1.52 (0.75 to 3.09) 0.25
Risk (high/low and intermediate) 4.24 (1.06 to 17.05) 0.04
Operative method (PD/LR) 1.65 (0.69 to 3.93) 0.26
Presentation (asymptomatic/symptomatic) 0.92 (0.38 to 2.22) 0.85
LR, local resection; PD, pancreaticoduodenectomy.
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with imatinib, while nine patients (18.8%) received post-
operative adjuvant imatinib with no local recurrence or
metastasis (Table 3).
The median duration of follow-up was 36 (range: 0 to
81) months. During follow-up, of 48 patients, 43 patients
were alive and free of recurrence; one patient died due
to an intra-abdominal hemorrhage within 1 month of
surgery; one patient died 35 months after the operation
due to a myocardial infarction; three patients had recur-
rence and the risk classifications were all high risk: one
patient underwent PD because of GIST recurrence after
LR (24 months) and two patients who had undergone
PD had liver metastases and did not receive further spe-
cial treatment (18 and 26 months). The 1- and 3-year
DFS rates were 100% and 88%, respectively. Multivari-
able analysis showed that patient age, sex, presence of
symptoms and operative method were not associated
with DFS. The only significant factor associated with a
worse DFS was an NIH high risk classification (hazard
ratio (HR) = 4.24, P = 0.04) (Table 4).
Discussion
Duodenal GISTs are a rare tumor entity, accounting for
4% of GISTs [10]. The clinical manifestations of duodenal
GISTs are variable depending on tumor size and the exist-
ence of mucosal ulceration. As in previous reports, in our
study, gastrointestinal bleeding was the most common
clinical presentation of a duodenal GIST, followed byTable 3 Complications and treatment details after
resection of a duodenal gastrointestinal stromal tumor
Variable Number of patients
(percentage of total number of patients)
Complications
Pancreatic fistula 6 (12.5%)















Other 2 (4.2%)incidental finding, abdominal discomfort and abdominal
pain. In general, duodenal GISTs most frequently involve
the second portion of the duodenum, followed by the
third portion, fourth portion and first portion. In the
current study, we also noted that the second portion of
the duodenum (35.4%) was most commonly involved,
while we also found a high incidence of lesions in the first
portion (22.9%). Furthermore, the median size of duodenal
GISTs in our series was 4.7 cm. Similarly, most authors re-
port a smaller size of tumor (4.0 to 5.0 cm) for duodenal
GISTs compared with gastric and small bowel GISTs
[6,8,11]. Interestingly, we noted that patients who ultim-
ately required PD were more likely to present with a larger
tumor and more commonly presented with a tumor in the
second portion of the duodenum compared with LR. So
we suggest that a tumor in the second portion of the duo-
denum, and which involves the papilla, pancreas or the
duodenal bulb, or if the tumor is large with a high malig-
nant potential, then PD is mandated since this type of
tumor usually cannot be locally resected.
Surgical resection with a clear margin is the best op-
tion for the treatment of GISTs [7-9,12]. The size of the
surgical margin along the segment of the digestive tract
is not formally defined; however, there is little submuco-
sal spread in GIST and clear margins of 1 or 2 cm are
recommended. Theoretically, the choice of surgical pro-
cedure for a duodenal GIST mainly depends on its size,
location and proximity to the duodenal papilla. However,
the optimal surgical procedure for a duodenal GIST is cur-
rently unknown. Various surgical procedures have been
reported, such as pancreaticoduodenectomy (PD) and
local resection (LR), including wedge or segmental resec-
tion. Some authors advocate radical procedures like PD
when the tumor is located at the medial wall of the second
portion of the duodenum and involves the ampulla of
Vater, or if the tumor has involved the adjoining organs
[8,9,13]. Whereas, others support LR based on the tumor’s
biology; since they are encapsulated tumors, GISTs do not
widely infiltrate at the microscopic level and rarely
metastasize to lymph nodes. As reported, LR can be used
if the resection can achieve histologically clear margins
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duodenum and common bile duct without the cost of in-
creased disease recurrence [7,14-16]. LR can be beneficial
for patients because it contributes to a better quality of life
and does not involve the excessive resection associated
with PD. However, the main concern regarding LR is the
risk from the margins involved and hence the theoretical
increased risk of local recurrence [7].
Whilst there are several case reports and series about
the clinicopathological features and frequency of duo-
denal GISTs, only a few reports compare the oncological
long-term outcome of LR versus PD. The largest series
of patients with duodenal GISTs (n = 156) indicated that
prognosis was associated with tumor grade. In this re-
view, 84 patients underwent LR (15 enucleations, 48 seg-
mental resections and 21 wedge resections, 80%) and 21
(20%) underwent PD, and the retrospective analysis did
not address the effect of operative method on disease re-
currence after the operation [5]. Very recently, Johnston
et al. retrospectively reviewed 96 patients at five institu-
tions, and there were 58 LRs and 38 PDs. They concluded
that factors associated with a worse recurrence-free sur-
vival included tumor size, mitotic count, being AJCC stage
III disease and an NIH high risk classification rather than
surgical approach [9]. Tien et al. analyzed nine patients
who underwent PD and sixteen who underwent LR. They
also showed that type of operation was not correlated to
operative risk and disease recurrence [7]. Of thirteen pa-
tients reported by Beham et al., eight underwent segmen-
tal duodenectomy and five underwent pylorus-preserving
PD. They suggested that the operative procedure and type
of mutation (the KIT and PDGFRA receptor tyrosine kin-
ase genes and comparative genomic hybridization) did not
correlate with long-term survival [17]. In the present
study, we noted that LR did not seem to have an adverse
impact on the longer-term outcomes of patients. Multivar-
iable analysis showed that operative method was not asso-
ciated with DFS. The only significant factor associated
with a worse DFS was an NIH high risk classification. Fur-
thermore, PD was significantly associated with a longer
operation time and a longer hospital stay compared to LR.
Collectively, these data indicate that LR might be a reliable
and curative option for a significant subset of patients with
duodenal GIST, which is in accordance with the report of
El-Gendi [18].
In the current study, the 1- and 3-year DFS was 100%
and 88%, respectively. This is similar to previous reports,
which showed that the DFS rate at 1 to 3 years after a
complete surgical resection, for all kinds of resection,
varies from 86% to 100% [8,13,16,18]. Prognosis and re-
currence are mainly dependent on tumor biology, which
is determined by size and mitotic index (Fletcher scale)
[19]. In our study, 75% of patients with a duodenal GIST
had a low mitotic count, which is consistent with thefindings reported by others (72% to 78%) and is lower
than for gastric and small bowel tumors (where a mitotic
count >5/50 HPF has been found in more than 30% of
cases) [6-9,18]. The data from the study by Miettinen et al.
also indicated that the prognosis for localized duo-
denal GISTs was poor with a high risk of relapse (>50%)
[5]. Due to the earlier presentation, smaller tumors and
a lower NIH risk classification, patients with a duodenal
GIST may belong in a better prognostic category than
other small bowel GISTs.
Imatinib mesylate, a tyrosine kinase inhibitor, plays a
key role in the management of GISTs. It can be used in
neoadjuvant therapy, adjuvant therapy and to treat tumor
recurrence [20]. The role of neoadjuvant imatinib mesylate
in the management of GISTs is currently the subject of an
ongoing multicenter trial. In our study, 9 of 48 patients re-
ceived postoperative adjuvant imatinib and there was no
local recurrence or metastasis.
Conclusions
Because the recurrence of a duodenal GIST is correlated
to tumor biology rather than type of operation, LR with
clear surgical margins is a reliable and curative option
for duodenal GISTs, and is compatible with long-term
DFS. PD should be reserved for patients where LR is not
technically feasible because of the involvement of the
papilla of Vater.
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